We hypothesize that a next-generation CoV vaccine that incorporates highly conserved and early-expressed RTC antigens selectively targeted by CD4+ and CD8+ T cells from asymptomatic COVID-19 patients and “SARS-CoV-2 aborters” would confer stronger, broader, and longer-lasting protective immunity against rapidly transmissible and highly pathogenic VOCs. The gene discussed is CD4; the disease is COVID-19.